Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wellstat Management Co. LLC

Latest From Wellstat Management Co. LLC

Alexion Nabs Valuable Voucher On Strensiq Approval

Alexion Pharmaceuticals Inc. not only gained the FDA's approval on Oct. 23 for Strensiq (asfotase alfa) as a treatment for patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP), but the win also garnered the company a rare pediatric disease priority review voucher (PRV), potentially putting hundreds of millions of dollars in the firm's pocket.

Infectious Diseases Orthopedics

Stockwatch: An Ultimate Answer To A Drug Pricing Question

Last week was one of those weeks that makes you grateful that the stock markets close for the weekend. While the preparations and arrival of Pope Francis brought much of New York's Fifth Avenue and its surrounds to a standstill as Thursday wore on, it was a shame that his presence in the city could not have had the same effect on the stock markets based there.

Metabolic Disorders Infectious Diseases

US Capitol Capsule: Buckle Up, Drug Makers: Bumpy Pricing Roads Ahead

It's unclear now whether legislation introduced late last week that seeks to rein in drug prices will gain enough support to actually go anywhere on Capitol Hill.

Metabolic Disorders Cardiovascular

AstraZeneca Scores 'Voucher' On Wellstat's Xuriden Approval

The FDA's approval on Sept. 4 of Wellstat Therapeutics' hereditary orotic aciduria (HOA) treatment Xuriden (uridine triacetate) means AstraZeneca has gained a coveted rare pediatric disease priority review voucher – a deal the two firms made last year, long before the so-called golden tickets were being sold for hundreds of millions of dollars.

See All

Company Information

  • Industry
  • Services
  • Other Names / Subsidiaries
    • Wellstat Group